✦ LIBER ✦

Surgical adjuvant chemotherapy. Results with one short course with cyclophosphamide after mastectomy for breast cancer

✍ Scribed by Roar Nissen-Meyer; Kjell Kjellgren; Kai Malmio; Bror Månsson; Torsten Norin

Publisher: John Wiley and Sons
Year: 1978
Tongue: English
Weight: 726 KB
Volume: 41
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(197806)41:6<2088::aid-cncr2820410604>3.0.co;2-j

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Evaluation of the worth of Corynebacteri

Evaluation of the worth of Corynebacterium parvum in conjunction with chemotherapy as adjuvant treatment for primary breast cancer: Eight-year results from the national surgical adjuvant breast and bowel project B-10

✍ Bernard Fisher; Ann Brown; Norman Wolmark; Edwin R. Fisher; Carol Redmond; D. La 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 854 KB

During the 1970s, information obtained from animal tumor models and from patients with a spectrum of solid tumors indicated the worth of a variety of immunostimulating agents. These findings provided a biological and clinical rationale for conducting randomized trials to evaluate the worth of those

Decreased immunoreactivity for p27 prote

Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status : Results from International Breast Cancer Study Group Trial V

✍ Vito J. Spataro; Heather Litman; Giuseppe Viale; Fausto Maffini; Michele Masullo 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 117 KB 👁 1 views

## Abstract ## BACKGROUND The objective of this study was to clarify the prognostic and predictive value of immunoreactivity for the cyclin‐dependent kinase inhibitor p27(Kip1) in patients with early‐stage breast carcinoma and to investigate its relation with clinicopathologic features and other m

Phase 2 trial of primary systemic therap

Phase 2 trial of primary systemic therapy with doxorubicin and docetaxel followed by surgery, radiotherapy, and adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil based on clinical and pathologic response in patients with stage IIB to III breast cancer : Long-term results from The University of Texas M. D. Anderson Cancer Center Study ID97-099

✍ Ricardo H. Alvarez; Daniel J. Booser; Massimo Cristofanilli; Aysegul A. Sahin; E 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 199 KB 👁 2 views